Clinical trials
catalyst calendar across sponsors →Studies where JNJ is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 observational · 1 with posted results
Held by 24 tracked-famous managers (MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, Squarepoint Ops LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +19 more) · FINRA short interest 3.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: 6 congress / 7 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Multicenter Postmarket Surveillance Registry Evaluating Performance and Long Term Safety of the Presillion StentNCT00968019results2013-03-06observationalMajor Cardiac Adverse Events (Including Cardiac Death, Myocardial Infarction (Q-wave and Non Q-wave) and Clinically Driven TLR (Target Lesion Revascularization)) | — | Completed | Device: Presillion stent | Coronary Arteriosclerosis | 318 | Apr 2011actual | 2013-03-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19